About the PERL Study

What is the PERL Study?

The PERL Study is a clinical trial designed to test whether the medication allopurinol can prevent or slow down kidney disease in people with type 1 diabetes. 530 people with type 1 diabetes are now participating in PERL. In PERL, kidney function is measured periodically to see if this treatment is effective. All study-related tests are provided at no charge.

Who is participating in PERL?

Individuals who were 18-70 years old, had type 1 diabetes for at least 8 years, and had early signs of decreased kidney function on blood and/or urine tests were recruited and are currently participating in the study. From these over 500 participants, about 34% are female and 66% are male, average age is 51 years old and they have had type 1 diabetes for about 34 years. Patients are participating from several locations across 3 countries: US, Canada, and Denmark.

How can I continue contributing to PERL?

The investigators and the whole PERL team are very fortunate in having such a committed group of study participants. You can continue collaborating in many ways, including:

Without your active participation, there is no study, and we will not be able to determine whether or not this therapy can help patients with diabetes.